ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
C-reactive protein and risk of lung cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 4 syntheses or guidelines pooled it, 216 citations in OpenAlex.
- Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.International journal of molecular sciences · 2023Pooled it
- Genetic polymorphisms in C-reactive protein increase cancer susceptibility.Scientific reports · 2016Pooled it
- Pooled it
- Inflammatory and Insulinemic Dietary Patterns: Influence on Circulating Biomarkers and Prostate Cancer Risk.Cancer prevention research (Philadelphia, Pa.) · 2020Trial
- Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015Trial
- Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study.American journal of epidemiology · 2013Trial
- Helicobacter pylori seropositivity and risk of lung cancer.PloS one · 2012Trial
- Circulating markers of interstitial lung disease and subsequent risk of lung cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Trial
- Lung cancer chemoprevention with celecoxib in former smokers.Cancer prevention research (Philadelphia, Pa.) · 2011Trial
- The use of blood test trends in cancer detection: a scoping review.Diagnostic and prognostic research · 2026Review
- Epigenetic inflammation signatures and lung cancer risk among never-smoking women: a nested case-control study.medRxiv : the preprint server for health sciences · 2026Article
- Towards Personalised Screening for Lung Cancer: A Sex-Stratified Approach in a Danish Cohort Integrating Pre-Diagnostic Systemic Inflammatory Indexes with Smoking Status and Age.Respiration; international review of thoracic diseases · 2026Article
- Integration of circulating tumor DNA data enhances lung cancer prediction in patients with COPD.Scientific reports · 2026Article
- Inflammatory cytokines and specific factors influencing lung cancer progression.Cancer pathogenesis and therapy · 2025Review
- The Relationship Between Non-Traumatic Fat Embolism and Fat Embolism Syndrome (FES) in Patients with Cancer.Diseases (Basel, Switzerland) · 2025Article
- Multi-Omics Analysis of the Epigenetic Effects of Inflammation in Murine Type II Pneumocytes.International journal of molecular sciences · 2025Article
- Cancer, malnutrition and inflammatory biomarkers. Why do some cancer patients lose more weight than others?Contemporary oncology (Poznan, Poland) · 2025Article
- Association between the dietary inflammatory index and risk of lung cancer: a multi-centered case-control study.BMC cancer · 2024Article
- Mendelian randomization analysis using multiple biomarkers of an underlying common exposure.Biostatistics (Oxford, England) · 2024Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeChronic inflammation could play a role in lung carcinogenesis, underscoring the potential for lung cancer prevention and screening. We investigated the association of circulating high-sensitivity C-reactive protein (CRP, an inflammation biomarker) and CRP single nucleotide polymorphisms (SNPs) with prospective lung cancer risk. PATIENTS AND
methodsWe conducted a nested case-control study of 592 lung cancer patients and 670 controls with available prediagnostic serum and 378 patients and 447 controls with DNA within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (N = 77,464). Controls were matched to patients on age, sex, entry year, follow-up time, and smoking. We measured CRP levels in baseline serum samples and genotyped five common CRP SNPs.
resultsElevated CRP levels were associated with increased lung cancer risk (odds ratio [OR], 1.98; 95% CI, 1.35 to 2.89; P-trend < .001 for fourth quartile [Q4, > or = 5.6 mg/L] v Q1 [< 1.0 mg/L]). The CRP association did not differ significantly by histology, follow-up time, or smoking status, but was most apparent for squamous cell carcinomas (OR, 2.92; 95% CI, 1.30 to 6.54), 2 to 5 years before lung cancer diagnosis (OR, 2.33; 95% CI, 1.24 to 4.39), and among former smokers (OR, 2.48; 95% CI, 1.53 to 4.03) and current smokers (OR, 1.90; 95% CI, 1.06 to 3.41). Although CRP SNPs and haplotypes were associated with CRP levels, they were not associated with lung cancer risk. Ten-year standardized absolute risks of lung cancer were higher with elevated CRP levels among former smokers (Q4: 2.55%; 95% CI, 1.98% to 3.27% v Q1: 1.39%; 95% CI, 1.07% to 1.81%) and current smokers (Q4: 7.37%; 95% CI, 5.81% to 9.33% v Q1: 4.03%; 95% CI, 3.01% to 5.40%).
conclusionElevated CRP levels are associated with subsequently increased lung cancer risk, suggesting an etiologic role for chronic pulmonary inflammation in lung carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.